Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POPSTAR: Cobolimab plus Dostarlimab in Pediatric and Young Adult Tumors
2024-511350-41-00Phase 2Completed
- Sponsor
- GSK
- Start
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 9
01
Overview
Phase 2, open-label trial of cobolimab and dostarlimab in melanoma, Hodgkin lymphoma (HL), high-grade glioma (HGG) and 10 more (4 arms), sponsored by GSK. Primary endpoints: Incidence of dose-limiting toxicities (DLTs), Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), immune-mediated adverse events (imAEs), and AEs leading to discontinuation (Part 1) and 5 more. Started Oct 2024; status: completed.
02
Drugs
cobolimabdostarlimab
03
Conditions
melanomaHodgkin lymphoma (HL)high-grade glioma (HGG)gliomaglioblastoma (GBM)
Beyond the preview
Go deeper on 2024-511350-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511350-41-00.